Leiderdorp

• BB trial; Effect of botox in Piriformis syndrome Pending
  2023-504427-61-01 6 piriformis hypertonia
• OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending
  2025-520554-11-00 5 Cardiovascular Disease
• An extension study to investigate the long-term safety and tolerability of itepekimab in adult participants with inadequately controlled chr … Pending
  2025-522983-33-00 5 Chronic rhinosinusitis with nasal polyps
• An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting
  2024-519870-38-00 5 2026-05-11 Atherosclerotic cardiovascular disease (ASCVD)
• Evaluation of the omission of dexamethasone in premedication regimens during paclitaxel treatment Recruiting
  2023-507481-43-00 11 2024-06-25 Solid tumors
• A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney D … Recruiting
  2025-523123-22-00 5 2026-05-07 Chronic Kidney Disease
• HF-POLARIS: A research study to look at how well NNC0487-0111 works compared to placebo in people with heart failure and obesity Recruiting
  2025-523717-29-00 5 2026-04-28 HFpEF or HFmrEF and obesity
• A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosi … Recruiting
  2025-521546-23-00 5 2026-04-21 Secondary progressive multiple sclerosis
• Low dose ColchicinE in pAtients with peripheral artery DiseasE to address residual vascular Risk: A randomized trial- LEADER PAD Recruiting
  2024-512091-35-01 5 2025-06-17 Peripheral arterial disease
• A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration ( … Recruiting
  2023-510294-34-00 5 2025-06-12 small lymphocytic lymphoma (SLL)
• Stopping or continuing blood thinners after stroke at young age without a known cause: STOP trial Recruiting
  2024-513092-40-00 6 2024-12-05 Stroke
• Timing of start of systemlc treatment for asymptomatic MEtastasized PANcreatic cancer (TIMEPAN): a prospective multicenter patient preferenc … Recruiting
  2023-509465-20-00 5 2024-10-28 metastatic pancreatic cancer
• DISTINCT: inDividual, targeted thrombosIS prophylaxis versus the standard ‘one size fits all’ approach in patients undergoing Total hIp or t … Recruiting
  2023-510186-98-00 6 2024-10-23 Venous thromboembolism
• A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Recruiting
  2023-509706-30-00 5 2024-10-18 Heart failure (HF)
• DOSAgE study: A multicenter randomized phase III trial of DOSe-reduced Chemotherapy for Advanced Colorectal Cancer in Older patients Recruiting
  2023-506115-17-00 5 2024-10-14 Metastatic Colorectal Cancer
• Trastuzumab Deruxtecan (T-DXd) for Subjects with Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC0 Breast Cancer … Recruiting
  2023-505616-38-00 4 2024-09-04 Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (
• FeAsiBility of a treatment free interval in newly diagnosed mUltiple myeLOma patients treated with DaratumUmab-Lenalidomide-DexamethaSone – … Recruiting
  2023-508586-33-00 5 2024-05-14 multiple myeloma
• The RiCOTTA study: Rifampicin Combination Therapy versus Targeted Antibiotic Monotherapy for Infected Joint Prostheses Caused by Staphylococ … Recruiting
  2022-501620-26-00 6 2023-05-15 prosthetic joint infection
• An European multinational study of a personalized approach of human albumin administration in patients with cirrhosis of the liver and compl … Recruiting
  2022-501006-34-01 5 2023-03-29 Liver cirrhosis
• Renal Lifecycle Trial: A Randomized Controlled Clinical Trial to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in … Recruiting
  2023-508389-13-00 5 2022-11-08 Combined endpoint of all-cause mortality, kidney failure, and hospital
• A Phase 3 study to assess the efficacy, safety, and tolerability of itepekimab (anti­IL­33 mAb) in participants with inadequately-controlled … Ended recruitment
  2024-516814-39-00 5 2025-05-20 Chronic rhinosinusitis with nasal polyps
• Personalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosis (NEXT-MS) Ended recruitment
  2024-513105-31-00 6 2024-07-30 Multiple Sclerosis
• DUTCH-WAIST Ended recruitment
  2022-501392-81-00 6 2024-07-25 Obesity
• A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascu … Ended recruitment
  2022-502781-24-01 5 2024-06-05 ASCVD - Atherosclerotic Cardiovascular Disease

Showing 1–24 of 36 trials